Expectations trend
FY2028 · fiscal year ending 2028-03-31 · fmp
Immunovant, Inc. (IMVT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$29.90+2.96%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMVT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Positive clinical trial results for IMVT-1402 | Positive trial data boosts confidence. | Intact | Negative trial results or regulatory setbacks occur | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-development exposure, not a proven earnings compounder. The multi-year view is on watch: management says IMVT-1402 timelines remain on track, but the evidence snapshot gives low confidence and recent financial performance is weak.
The evidence provides no valuation measure or direct account of market expectations, so whether the shares are cheap, fair, or expensive versus peers cannot be assessed. The snapshot does flag weak performance relative to the industry cohort, but that alone does not show what expectations are already reflected.
Near term, consecutive earnings misses and an elevated risk of another miss make results a key concern. Over the multi-year view, management reports clinical timelines on track across six indications, with topline data expected from 2026 through 2028; cash declined between the first and second quarters of 2026. The sector backdrop is a tailwind, but the evidence for near-term operating improvement is thin.
The thesis depends on IMVT-1402 advancing on schedule and producing useful data across its indications, alongside adequate resources for a potential Graves' disease launch. A guidance cut or further weak results would add concern, while continued strength among healthcare bellwethers could support the sector backdrop.
For the next 1 to 3 years, IMVT is a high-risk clinical-development story with meaningful execution and earnings uncertainty. Its long-term thesis hinges on IMVT-1402 progress, while current evidence does not establish whether valuation already reflects that risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Immunovant, Inc.'s published investment case. The stated target is EPS loss narrows from -$2.44 in FY27 to less negative in FY28. |
| Intact |
| EPS loss worsens beyond -$2.44 in FY28 |
Diluted EPS: $-0.75 per share FY2027-Q1; GAAP. Published target: EPS loss narrows from -$2.44 in FY27 to less negative in FY28. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-0.75 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stable leadership and R&D team | A supporting condition in Immunovant, Inc.'s published investment case. The stated target is No further key executive departures through FY27. | Intact | Loss of key executives or R&D disruption | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Start generating meaningful revenue from product sales | A primary condition in Immunovant, Inc.'s published investment case. The stated target is Achieve >$37 million revenue in FY28. | Intact | Revenue falls below $20 million in FY28 | Revenue: $7.095M FY2027-Q1; GAAP. Published target: Achieve >$37 million revenue in FY28. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20267,095,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.59 → $-2.92 · observed estimates
$0.06B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.59 | $59,489,609 | 8 / 9 |
| 2026-07-25 | $-2.59 | $59,489,609 | 8 / 9 |
| 2026-07-26 | $-2.59 | $59,489,609 | 8 / 9 |
| 2026-07-27 | $-2.05 | $39,659,740 | 3 / 12 |
| 2026-07-28 | $-2.05 | $39,659,740 | 3 / 12 |
| 2026-07-29 | $-2.05 | $39,659,740 | 3 / 12 |
| 2026-07-30 | $-2.05 | $39,659,740 | 3 / 12 |
| 2026-07-31 | $-2.13 | $36,608,990 | 4 / 13 |
| 2026-08-01 | $-2.58 | $52,879,652 | 7 / 8 |
| 2026-08-02 | $-2.13 | $36,608,990 | 4 / 13 |
| 2026-08-03 | $-2.13 | $36,608,990 | 4 / 13 |
| 2026-08-04 | $-2.13 | $36,608,990 | 4 / 13 |
| 2026-08-05 | $-2.58 | $52,879,652 | 8 / 9 |
| 2026-08-06 | $-2.58 | $52,879,652 | 8 / 9 |
| 2026-08-07 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-08 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-09 | $-2.33 | $33,994,060 | 5 / 14 |
| 2026-08-10 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-12 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-13 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-14 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-15 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-16 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-17 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-18 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-19 | $-2.69 | $48,541,687 | 9 / 9 |
| 2026-08-20 | $-2.80 | $44,128,806 | 8 / 9 |
| 2026-08-21 | $-2.80 | $44,128,806 | 8 / 9 |
| 2026-08-22 | $-2.80 | $44,128,806 | 8 / 9 |
| 2026-08-23 | $-2.89 | $46,845,010 | 8 / 9 |
| 2026-08-24 | $-2.89 | $46,845,010 | 8 / 9 |
| 2026-08-25 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-08-26 | $-2.92 | $42,941,259 | 9 / 9 |
| 2026-08-27 | $-2.92 | $42,941,259 | 9 / 9 |
| 2026-08-28 | $-2.92 | $42,941,259 | 9 / 9 |
| 2026-08-29 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-08-30 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-08-31 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-01 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-02 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-03 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-04 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-05 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-06 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-07 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-08 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-09 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-10 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-11 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-12 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-13 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-14 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-15 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-16 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-17 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-18 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-19 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-20 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-21 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-22 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-23 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-24 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-25 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-26 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-27 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-28 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-29 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-09-30 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-01 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-02 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-03 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-04 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-05 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-06 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-07 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-08 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-09 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-10 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-11 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-12 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-13 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-14 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-15 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-16 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-17 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-18 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-19 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-20 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-21 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-22 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-23 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-24 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-25 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-26 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-27 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-28 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-29 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-30 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-10-31 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-11-01 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-11-02 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-11-03 | $-2.92 | $42,941,259 | 8 / 9 |
| 2026-11-04 | $-2.92 | $42,941,259 | 8 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.